Biomarker research investigating genetic polymorphisms in drug-metabolizing enzymes (CYP2D6, CYP3A4) and neurotransmitter receptors could identify patients at highest risk for developing medication-induced bowel dysfunction, enabling personalized medicine approaches. The gene discussed is CYP2D6; the disease is bowel dysfunction.